VistaGen Therapeutics (VTGN) investor relations material

Platform and pipeline overview

• Five clinical-stage candidates developed from a pherine platform, all delivered as non-systemic nasal sprays targeting chemosensory neurons in the nasal passage.

• Lead asset, Fasedienol, is in phase III for acute treatment of social anxiety disorder; other assets target major depressive disorder, mental fatigue, women's health (vasomotor symptoms, PMDD), and cancer cachexia.

• Non-systemic delivery avoids typical side effects and abuse liability, offering rapid onset and patient agency in use.

Clinical development and trial insights

• Fasedienol's PALISADE program uses a public speaking challenge paradigm to assess efficacy in social anxiety disorder, with endpoints based on the Subjective Units of Distress Scale.

• PALISADE-2 showed statistically significant separation from placebo, marking the first positive phase III study in this setting; PALISADE-4 is ongoing with readout expected by end of H1 2026.

• Consistent treatment effects observed across studies, with placebo variability being a key focus for mitigation through operational and analytical adjustments.

• Open label studies with nearly 500 subjects and 30,000 doses demonstrated strong safety (headache most common adverse event) and real-world efficacy, with patients showing month-over-month improvement.

Data analysis and regulatory strategy

• AI and machine learning are being used to analyze vocal biomarkers and covariates from trial data to refine statistical analysis plans and mitigate placebo effects.

• Adjustments to the statistical analysis plan (SAP) are considered before database lock, with time allocated for agency review.

• Multiple regulatory pathways are being considered: conventional two pivotal trials, a single pivotal trial with compelling evidence, or complementary study designs (e.g., Liebowitz-based study).